Synthekine

Designing Fresh Approaches to Overcome Cytokine Limitations

Two Approaches in the Clinic for IL-2: Lead clinical programs utilize a familiar cytokine (IL-2) in new ways, including as a highly selective partial agonist designed to avoid toxicities and in an orthogonal system designed to control activity, durability and persistence of a CD19 CAR-T
- Unveiled positive initial clinical first-in-human data from Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012 in solid tumors at AACR 2024
Dynamic pipeline driven by cytokine engineering platforms across oncology, autoimmune & inflammatory indications:
- Three platforms – partial agonists, orthogonal systems and surrogate cytokine agonists
- Advancing CAR-T therapy for autoimmune into new clinical areas, including systemic lupus erythematosus (SLE)
Key Events in 2025: Advancing lead clinical programs through clinical investigation to initial clinical trial data readouts; Advancing additional partial agonist systems toward clinical investigation; building on partnerships with Sanofi (2024) and Merck (2022), Expanding orthogonal system for autoimmune disease into SLE without use of lymphodepletion and other disease areas